Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?
In June 2024, WHO released ‘Key updates to the treatment of drug-resistant tuberculosis: rapid communication’, after the preliminary publication of results from two clinical trials: ‘BEAT-Tuberculosis’ and ‘endTB’. All proposed regimens include clofazimine (Cfz). However, a recent paper has reported...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-11-01
|
| Series: | IJTLD Open |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000011/art00002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | In June 2024, WHO released ‘Key updates to the treatment of drug-resistant tuberculosis: rapid communication’, after the preliminary publication of results from two clinical trials: ‘BEAT-Tuberculosis’ and ‘endTB’. All proposed regimens include clofazimine (Cfz). However, a recent paper has reported a high incidence of QTc prolongation among patients receiving Cfz-based treatment for multidrug-resistant TB in Taiwan. Here, we discuss the cardiac safety of Cfz and the role of active drug safety monitoring at the programme level in collecting information on this issue. |
|---|---|
| ISSN: | 3005-7590 |